<DOC>
	<DOC>NCT02603406</DOC>
	<brief_summary>Neovascularization Induced by Mechanical Barrier disrUption and Systemic erythropoietin in patients with cerebral perfusion deficits (NIMBUS trial)</brief_summary>
	<brief_title>Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Acute period (ischemic stroke confirmation on DWI or TIA within 7 days after symptom onset) Below 20 point of initial NIHSS score within 7 days after stroke onset and enrolment. Confirmation of atherosclerotic or stenoocclusive stroke mechanism (proximal cerebral arteries) on CTA or MRA . At least hemodynamically, perfusion status of a candidate is stage II or III (decrease of regional Cerebral blood flow on CBF map) If female then not of childbearing potential Informed consent Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arteriovenous malformation (AVM), cerebral aneurysm, or cerebral neoplasm Treated with a thrombolytic &lt;24 hours (if &gt;24 hours and excluded ICH then eligible) Score &gt;=1 on the NIHSS item 1a Prestroke mRS score &gt;=2 Uncontrolled hypertension Previous treatment with erythropoietin At screening: Hemoglobin &gt;15 mg/dl, prolonged PT or PTT, serum Cr &gt;2.0 mg/dl,thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet count or white blood cell count, respectively (absolute neutrophil count of &gt; 1800/mm3 required for participation), or &gt; 2 times of normal on liver function tests (SGOT, SGPT, total bilirubin)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>